Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 15/20 | 0.82 |
| ▸ | IL2RA | P01589 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | IL2 | P60568 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19982260 | 1.00 | YAP1 (0.82) | YAP1IL2RAALBIL2 | |
| SCHEMBL21366138 | 0.93 | YAP1 (0.83) | YAP1IL2RAALBIL2 | |
| SCHEMBL21366132 | 0.93 | YAP1 (0.83) | YAP1IL2RAALBIL2 | |
| SCHEMBL19974553 | 0.93 | YAP1 (0.75) | YAP1 | |
| SCHEMBL23296224 | 0.93 | YAP1 (0.75) | YAP1 | |
| SCHEMBL19982111 | 0.92 | YAP1 (0.81) | YAP1IL2RAALBIL2 | |
| SCHEMBL19982110 | 0.92 | YAP1 (0.81) | YAP1IL2RAALBIL2 | |
| SCHEMBL19982104 | 0.90 | YAP1 (1.00) | YAP1IL2RAALBIL2 | |
| SCHEMBL19982256 | 0.90 | YAP1 (1.00) | YAP1IL2RAALBIL2 | |
| SCHEMBL21366277 | 0.90 | YAP1 (0.83) | YAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210130297-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10906874-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2018053446-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906874-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, IWS1, YES1 | YAP1 1/4885IL2RA 3561/4885ALB 4051/4885 |
| US-20210130297-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, YES1, MYC | YAP1 1/4885IL2RA 3956/4885ALB 3863/4885 |
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, YES1, MYC | YAP1 1/4885IL2RA 4016/4885ALB 3965/4885 |
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | YAP1, YES1, MYC | YAP1 1/4885IL2RA 3956/4885ALB 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.